Transaction · 0001104659-26-116966

Arch Venture Partners Xii, LLC

ARCH Venture Partners XII, LLC, 10%, reported an open-market or private purchase at CITY THERAPEUTICS, INC. involving 170000.000000 shares for an estimated $3060000.00. Reported holdings after the transaction were 13692507.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market buySEC transaction code P10%
CTYCITY THERAPEUTICS, INC.
Trade date
Oct 19, 2026
Filing date
Oct 19, 2026
View on SEC Insider profile
Estimated value$3.06MShares × reported price
Shares traded170k$18.00 per share
Holdings after13.6MIndirect · By ARCH Venture Fund XII, L.P.
% of reported position traded1.26%This security and ownership context
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 13,522,507 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CTY price since this filing

Daily closing prices, with the filing date and available return windows
CTY · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Buy
Code P
Identifier
0001104659-26-116966
Common Stock
Transaction date
Oct 19, 2026
Filed Oct 19, 2026, 09:38 PM · 0d delay
Shares
170,000 sh
$18.00 per share
Estimated value
$3.06M
Computed from shares × price
Holdings after
13,692,507 sh
Indirect · By ARCH Venture Fund XII, L.P.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Buy Large Buy 10% Owner Buy
Filing-only score

+44 points

Compact filing score computed from stored Form 4 facts. Version v1.

Strong filing signal

This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.

How this score is calculated
  • open_market_purchase+12 points

    transaction_code = P

    Code P is a discretionary open-market purchase.
  • ten_percent_owner_buy+4 points

    is_ten_percent_owner = true

    10% beneficial owner open-market purchase.
  • cluster_buy+14 points

    cluster-buy signal matched

    Multiple insiders bought within the configured window.
  • large_buy_absolute+10 points

    large-buy signal with absolute_triggered = true

    Open-market purchase exceeds the configured absolute threshold.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    Each share of Series Seed convertible preferred stock, Series A convertible preferred stock and Series B convertible preferred stock (collectively, the "Preferred Stock") was convertible into Common S…

  2. F2

    Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC")…

Original filing · 0001104659-26-116966
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CTY